Ligand Pharmaceuticals Incorporated Business Finance Contracts & Agreements

60 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Purchase and Sale Agreement, dated May 6, 2024, byand among Ligand Pharmaceuticals Incorporated,Agenus Inc., Agenus Royalty Fund, LLC, and AgenusHoldings 2024, LLC
Purchase Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2024
First Amendment to Credit Agreement, dated as of July 8, 2024, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors, the Lenders, and Citibank,...
Credit Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2024
Director Compensation and Stock Ownership Policy, as amended and restated effective August 4, 2023
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2023
Director Compensation and Stock Ownership Policy, as amended and restated effective April 19, 2023
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2023
Director Compensation and Stock Ownership Policy, as amended and restated, effective April 13, 2020
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2023
Form of Restricted Stock Unit Award Agreement under the Companys 2022 Employment Inducement Plan
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2022
Form of Stock Option Agreement under the Companys 2022 Employment Inducement Plan
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2022
Contingent Value Rights Agreement, dated as of September 30, 2020, by and between Ligand Pharmaceuticals Incorporated and American Stock Transfer & Trust Company, LLC
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2020
Asset Purchase Agreement, dated February 11, 2020, (as amended on April 1, 2020), by and among the Registrant, Icagen Inc., Icagen Corp., XRPro Sciences, Inc. and Caldera...
Purchase Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2020
Amended and Restated Director Compensation and Stock Ownership Policy, effective March 28, 2019
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2020
Asset Purchase Agreement, dated March 5, 2019, by and among Ligand Pharmaceuticals Incorporated and RPI Finance Trust
Purchase Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2019
Supplemental Indenture, dated as of February 20, 2018, between the Company and Wilmington Trust, National Association, as trustee
Indenture Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 18, 2018, between Goldman Sachs & Co. LLC and the Company regarding the Additional Warrant Transaction
Warrant Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Warrant Transaction
Warrant Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 18, 2018, between Deutsche Bank AG and the Company regarding the Additional Convertible Note Hedge Transaction
Note Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Warrant Transaction
Warrant Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 18, 2018, between Barclays Capital Inc. and the Company regarding the Additional Convertible Note Hedge Transaction
Note Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Warrant Transaction
Warrant Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 17, 2018, between Deutsche Bank AG and the Company regarding the Base Convertible Note Hedge Transaction
Note Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Warrant Transaction
Warrant Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
Letter Agreement, dated as of May 17, 2018, between Barclays Capital Inc. and the Company regarding the Base Convertible Note Hedge Transaction
Note Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2018
LIGAND PHARMACEUTICALS INCORPORATED AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 22, 2018 0.75% Convertible Senior Notes due 2023 TABLE OF...
Indenture Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2018
Third Amendment to Loan and Security Agreement
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2017
LIGAND PHARMACEUTICALS INCORPORATED DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (Amended and Restated Effective March [ ], 2014) I. DIRECTOR COMPENSATION
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2016
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY...
Exchange Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2016
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2016
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2015
LIGANDPHARMACEUTICALS INCORPORATED AS ISSUER 0.75% CONVERTIBLE SENIOR NOTES DUE 2019 INDENTURE DATED AS OF AUGUST 18, 2014 WILMINGTON TRUST, NATIONAL ASSOCIATION AS TRUSTEE TABLE...
Indenture Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
DE
2014
LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2014
LIGAND PHARMACEUTICALS INCORPORATED NOTICE OF GRANT OF STOCK OPTION
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2014
LIGAND PHARMACEUTICALS INCORPORATED DOCS ATM financing facility $24,000,000 of Common Stock, $0.001 par value SALES AGREEMENT October 11, 2013
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2013
LIGAND PHARMACEUTICALS INCORPORATED Common Stock (par value $0.001 per share) At the Market Issuance Sales Agreement
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2013
ROYALTY STREAM AND MILESTONE PAYMENTS PURCHASE AGREEMENT
Purchase Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2013
SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2013
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2012
LIGAND PHARMACEUTICALS INCORPORATED Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement
Stock Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2012
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2012
JOINDER AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
Loan Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2012
SECURED PROMISSORY NOTE
Note Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2012
SECURED PROMISSORY NOTE
Note Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2012